Akebia Therapeutics, Inc. (AKBA), which recently launched its oral chronic kidney disease anemia drug, Vafseo, in the U.S., is optimistic that 2025 will be a transformative year for the company.
Vafseo received FDA approval in March 2024 for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months and was launched in the U.S. early this month.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.